It's all about the lips with the soon-to-be-acquired company's latest advertising push.
News & Analysis: Allergan
Despite Humira's declining international sales, AbbVie is still worth considering.
The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.
The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.
A pair of deals will remove some regulatory impediments to the merger.
The clock's ticking on this big pharmaceutical buyout.
AbbVie's shares had an off year in 2019. Here's why.
The stock has already rallied 20% over the past three months, and with a new drug in the mix, it could continue to climb even higher.
The company is leaving the aesthetics unit largely intact.
The stock is trading near its 52-week high even though its returns are flat this year.